A Case of Babesiosis Complicated by Hepatic and Renal Failure
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Case Report

A 67-year-old male with a past medical history of chronic kidney
insufficiency, splenectomy, and recurrent babesiosis infection
was transferred to with jaundice and abdominal pain.
The patient initially presented to an outside hospital (OSH) with
generalized weakness, chills, and gastrointestinal symptoms and
was found to have Babesia on peripheral blood smears. The
patient received seven days of azithromycin and atovaquone,
followed by three days of clindamycin and quinine sulfate.
The patient was discharged home with improved symptoms
and a negative peripheral blood smear. Less than 24 hours
later he returned to the OSH with worsening myalgias and
abdominal pain. Physical exam was significant for jaundice
and hepatomegaly. Laboratory data revealed anemia, elevated
creatinine, bilirubin of 30 mg/dL, and 1% parasitemia. At this
point the patient was transferred for further management.
Patient’s past medical history was significant for chronic renal
insufficiency, congestive heart failure, type 2 diabetes mellitus,
coronary artery disease, and hypertension. Previous surgical
procedures included splenectomy after a motor vehicle accident,
below the knee amputation (BKA) of the right leg, and cholecystectomy. Patient denied alcohol or substance abuse, and quit
smoking tobacco approximately 10 years ago. He is a retired
carpenter and denied any recent history of travel. Medications
on admission included digoxin, clopidogrel, isosorbide
mononitrate, carvedilol, sucralfate, esomeprazole, metoclopramide, amlodipine, octreotide, and insulin lispro.
On examination, patient looked fatigued, but in no acute distress.
He was afebrile and had stable vital signs. Physical exam
was significant for scleral icterus, ventral hernia and diffuse
blanching, maculopapular rash on patient’s hands and soles.
Patient was admitted and started on treatment with clindamycin
and quinine. The patient’s blood smear showed Babesia
species with a 1.7% parasitemia (figure 1). During the hospital
stay, patient had an acute mental status change with asterixis.
Laboratory data obtained at that time revealed elevated INR,
bilirubin, and ammonia levels. Given the clinical findings,
patient was started on lactulose for possible hepatic encephalopathy. Hepatitis serology was found to be negative. Dialysis
was initiated in the setting of acute renal failure. Patient’s
clinical status continued to worsen, so red blood cell exchange
transfusion was initiated in an attempt to reduce the parasite load
and help clear the infection. Despite the exchange transfusion
and continued antibiotic treatment, the patient continued to have
hemolysis, paracitemia, renal failure, and hepatic failure. At that
point hospice discussion was initiated and patient was eventually
transferred to hospice home care.

Discussion

Babesiosis is a tick born protozoan infection of red blood cells
from the genus Babesia. The first human case was reported
in 19571. The four Babesia species that most commonly infect
humans in decreasing order of incidence are B. microti, B.
duncani, B. divergens, and B. venatorum. Babesiosis is a zoonotic
infection requiring both an animal reservoir (usually mice) and
a vector, which in humans is the Ixodid tick. The protozoan
is transmitted through the saliva of a tick when it bites. Other
possible modes of infection include perinatal transmission and
blood transfusion.
The endemic areas for babesiosis show significant overlap with
Lyme disease and ehrlichiosis2. The disease is most commonly
seen in the northeast of the United States, and the most common
cause of babesiosis in America is the B. microti species. While
the majority of the early cases were seen in coastal areas near
Massachsetts, babesiosis is now diagnosed with regularity in
Rhode Island, Connecticut, and even New York and New Jersey3.
Many cases have now been reported in other states stretching as
far west as California and even Europe has confirmed cases of
B. microti babesiosis.
The severity of babesiosis infection depends on the strain of
parasite as well as host factors such as immune system status or
asplenia. Clinically, patients infected with B.Microti typically fall
into one of three categories of disease expression: asymptomatic,
flu-like, and severe infection. Given the relatively high seroprevalence, many infected individuals are asymptomatic and unaware
they carry the parasite4. One study estimates the prevalence
of asymptomatic infection at about one third of infected
individuals5. However, most infected individuals fall into the
second category, mild to moderate flu-like illness. Similar to
Lyme disease, up to two thirds of these symptomatic patients
cannot recall getting bit by a tick, making diagnosis potentially
difficult6. Patients typically present with malaise and fatigue and
develop intermittent fevers with one of the following in order of
prevalence: chills, sweats, headaches, anorexia, cough, nausea.
Patients with severe disease more often present with malaise,
arthralgia, myalgia, and shortness of breath often combined with
thrombocytopenia and abnormal liver function7. Severe infection
carries with it the potential of numerous serious complications
including DIC, congestive heart failure, acute respiratory failure,
liver and renal failure, and splenic rupture.
Diagnosis of babesiosis infection is typically made by
microscopic examination and identification of the typical
appearance of organisms on Geimsa stained thin red blood cell
smears. Polymerase chain reaction (PCR) amplification, although
more expensive, is more sensitive than microscopic identification and can be completed within one day. For diagnostic
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Figure 1. RBC peripheral smear showing typical babesiosis organisms in the patient’s blood.
confirmation or when both microscopy and PCR are negative,
serologic diagnosis can also be made. The standard treatments
for babesiosis are the antibiotic regimens of clindmycin and
quinine, or atovaquone and azithromycin, both administered for
7 to 10 days. Infections with a high parasitemia load or those
that are persistent or relapsing might benefit from red blood cell
transfusion to lower the parasite level in the blood. However,
even with appropriate treatment, babesiosis can be fatal in
certain patient populations.
Although most cases of babesiosis in the United States are
mild to moderate or even asymptomatic, some cases are severe
and may be fatal. It is important to be wary of the potential
devastation the disease can have as well as who is more likely
to manifest severe disease. The risk factors for severe disease
include age older than 50, asplenia, coinfection with HIV or
Borrelia burgdorferi, and an immunocompromised state. The
case above demonstrates severe and resistant infection in the
setting of multiple risk factors, namely increased age and
asplenia. Though the patient was on appropriate antibiotic
treatment and received multiple red blood cell transfusions, he
still suffered from complications of the disease and was unable
to clear the infection.
This case demonstrates that babesiosis is a potentially severe and
fatal disease. It is important to recall the risk factors for disease
severity, especially in certain at-risk populations. In treating such
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populations, potential end of life issues should be considered, as
mortality and complications from the disease are significant.
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